{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:06:31Z","timestamp":1783533991488,"version":"3.55.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Midostaurin is a multikinase inhibitor for the treatment of Fms-like tyrosine 3 (FLT3)-mutated acute myeloid leukaemia (AML). Cardiac adverse events like QTc-prolongation, pericardial effusion, and congestive heart failure have been described. Inflammatory diseases associated with midostaurin are rarely reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 24-year-old man with newly diagnosed AML and FLT3-ITD mutation was treated with intensive remission-induction chemotherapy and midostaurin. After 5 days of midostaurin, the patient reported severe focal chest pain. Due to laboratory evidence of acute myocardial cell damage, coronary macroangiopathy and pulmonary artery embolism were ruled out via computed tomography. Cardiovascular magnetic resonance showed evidence for active perimyocarditis with myocardial oedema and late gadolinium of the basal, midventricular, and apical lateral wall of the left ventricle. Therapeutic drug monitoring did not reveal excessive midostaurin plasma levels, and hence, initially suspected drug interaction with posaconazole administered for antifungal prophylaxis was considered less likely to be causative. After discontinuing midostaurin, clinical signs of perimyocarditis improved. During continued high-dose cytarabine therapy, no further cardiac events occurred. It was concluded that perimyocarditis was an adverse effect of midostaurin since the inhibition of FTL3 may have led to a loss of cardiomyocyte protective capacity against oxidative stress-induced apoptosis, as previously described in vitro.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>In addition to the most frequently reported non-cardiac adverse effects of midostaurin, serious cardiotoxic complications appear to occur and may require discontinuation of therapy. This case highlights the importance of interdisciplinary work-up of a cardio-oncology pathway even in presumably low-risk patients and particularly in the context of rare cases of cardiotoxicity in novel cancer treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf044","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:21:21Z","timestamp":1741346481000},"source":"Crossref","is-referenced-by-count":3,"title":["Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1418-0389","authenticated-orcid":false,"given":"Alev","family":"Kalkan","sequence":"first","affiliation":[{"name":"Department III of Internal Medicine, Heart Center, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937, Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-9313","authenticated-orcid":false,"given":"Lenhard","family":"Pennig","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937, Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-5008","authenticated-orcid":false,"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[{"name":"Department III of Internal Medicine, Heart Center, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937, Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, ECMM Excellence Center for Medical Mycology , Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Stra\u00dfe 62, 50937, Cologne ,","place":["Germany"]},{"name":"Institute for Translational Research, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , University of Cologne, Herderstrasse 52, 50823 Cologne, NRW ,","place":["Germany"]},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Herderstrasse 52, 50823 Cologne, NRW ,","place":["Germany"]},{"name":"Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS K\u00f6ln), University of Cologne , Gleueler Strasse 269, 50935 Cologne, NRW ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-2469","authenticated-orcid":false,"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, ECMM Excellence Center for Medical Mycology , Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Stra\u00dfe 62, 50937, Cologne ,","place":["Germany"]},{"name":"Institute for Translational Research, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , University of Cologne, Herderstrasse 52, 50823 Cologne, NRW ,","place":["Germany"]},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Herderstrasse 52, 50823 Cologne, NRW ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2025030711464103900_ytaf044-B1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025030711464103900_ytaf044-B2","doi-asserted-by":"crossref","first-page":"A12978","DOI":"10.1161\/circ.142.suppl_3.12978","article-title":"Abstract 12978: identification of cardiovascular adverse effects associated with midostaurin\u2014a WHO Pharmacovigilance Database analysis","volume":"142","author":"Choudhary","year":"2020","journal-title":"Circulation"},{"key":"2025030711464103900_ytaf044-B3","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025030711464103900_ytaf044-B4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025030711464103900_ytaf044-B5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/jof8060583","article-title":"High incidence of invasive fungal diseases in patients with FLT3-mutated AML treated with midostaurin: results of a multicenter observational SEIFEM study","volume":"8","author":"Cattaneo","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2025030711464103900_ytaf044-B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J Hematol Oncol"},{"key":"2025030711464103900_ytaf044-B7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacc.2013.08.1647","article-title":"FLT3 activation improves post-myocardial infarction remodeling involving a cytoprotective effect on cardiomyocytes","volume":"63","author":"Pfister","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025030711464103900_ytaf044-B8","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/bjc.2017.88","article-title":"Tyrosine kinase-targeting drugs-associated heart failure","volume":"116","author":"Gronich","year":"2017","journal-title":"Br J Cancer"},{"key":"2025030711464103900_ytaf044-B9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/wjon1232","article-title":"Midostaurin-related interstitial lung injury in FLT3(+) acute myeloid leukemia post-allogeneic transplant","volume":"10","author":"Vaidya","year":"2019","journal-title":"World J Oncol"},{"key":"2025030711464103900_ytaf044-B10","first-page":"36","article-title":"Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia","volume":"7","author":"Kim","year":"2021","journal-title":"Cardiooncology"},{"key":"2025030711464103900_ytaf044-B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat Commun"},{"key":"2025030711464103900_ytaf044-B12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2025030711464103900_ytaf044-B13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ejh.14178","article-title":"Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: application to a cohort of patients with acute myeloid leukemia","volume":"112","author":"Wiesen","year":"2024","journal-title":"Eur J Haematol"},{"key":"2025030711464103900_ytaf044-B14","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/cts.13595","article-title":"Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: pharmacokinetic interactions and clinical facts in a real life study","volume":"16","author":"Menna","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025030711464103900_ytaf044-B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025030711464103900_ytaf044-B16","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"key":"2025030711464103900_ytaf044-B17","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/3\/ytaf044\/62313401\/ytaf044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/3\/ytaf044\/62313401\/ytaf044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:47:03Z","timestamp":1741348023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf044\/8058948"}},"subtitle":[],"editor":[{"given":"Diego","family":"Araiza-Garaygordobil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Elizabeth","family":"Paratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Faris","family":"Kad\u00edc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf044","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"ytaf044"}}